Correlation Between Avadel Pharmaceuticals and Aligos Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Avadel Pharmaceuticals and Aligos Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Avadel Pharmaceuticals and Aligos Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Avadel Pharmaceuticals PLC and Aligos Therapeutics, you can compare the effects of market volatilities on Avadel Pharmaceuticals and Aligos Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Avadel Pharmaceuticals with a short position of Aligos Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Avadel Pharmaceuticals and Aligos Therapeutics.

Diversification Opportunities for Avadel Pharmaceuticals and Aligos Therapeutics

-0.76
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Avadel and Aligos is -0.76. Overlapping area represents the amount of risk that can be diversified away by holding Avadel Pharmaceuticals PLC and Aligos Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Aligos Therapeutics and Avadel Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Avadel Pharmaceuticals PLC are associated (or correlated) with Aligos Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Aligos Therapeutics has no effect on the direction of Avadel Pharmaceuticals i.e., Avadel Pharmaceuticals and Aligos Therapeutics go up and down completely randomly.

Pair Corralation between Avadel Pharmaceuticals and Aligos Therapeutics

Given the investment horizon of 90 days Avadel Pharmaceuticals PLC is expected to under-perform the Aligos Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Avadel Pharmaceuticals PLC is 1.04 times less risky than Aligos Therapeutics. The stock trades about -0.2 of its potential returns per unit of risk. The Aligos Therapeutics is currently generating about -0.09 of returns per unit of risk over similar time horizon. If you would invest  3,984  in Aligos Therapeutics on October 21, 2024 and sell it today you would lose (560.00) from holding Aligos Therapeutics or give up 14.06% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Avadel Pharmaceuticals PLC  vs.  Aligos Therapeutics

 Performance 
       Timeline  
Avadel Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Avadel Pharmaceuticals PLC has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's fundamental indicators remain quite persistent which may send shares a bit higher in February 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.
Aligos Therapeutics 

Risk-Adjusted Performance

26 of 100

 
Weak
 
Strong
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Aligos Therapeutics are ranked lower than 26 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak technical and fundamental indicators, Aligos Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point.

Avadel Pharmaceuticals and Aligos Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Avadel Pharmaceuticals and Aligos Therapeutics

The main advantage of trading using opposite Avadel Pharmaceuticals and Aligos Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Avadel Pharmaceuticals position performs unexpectedly, Aligos Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aligos Therapeutics will offset losses from the drop in Aligos Therapeutics' long position.
The idea behind Avadel Pharmaceuticals PLC and Aligos Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.

Other Complementary Tools

Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
CEOs Directory
Screen CEOs from public companies around the world
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities